Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
Completed · Phase 3 · Has a placebo group
Conditions studied: Glabellar Frown Lines
In brief
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
Key facts
- Study ID
- NCT05146999
- Run by
- Galderma R&D
- People needed
- 132
- Starts
- 2022-05-09
- Expected to finish
- 2023-09-01
- Last updated by the study team
- 2024-10-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Male or Female 18 years or older
- Moderate to severe GL at maximum frown as assessed by the Investigator
- Moderate to severe GL at maximum frown as assessed by the subject
You may not qualify if…
- Previous use of any botulinum toxin in facial areas within 9 months prior to study treatment
- Female who is pregnant, breast feeding or intends to conceive a child during the study.
Where it is running
- Galderma Research Site — Homewood, Alabama, United States
- Galderma Research Site — Manhattan Beach, California, United States
- Galderma Research Site — Vista, California, United States
- Galderma Research Site — Coral Gables, Florida, United States
- Galderma Research Site — Hunt Valley, Maryland, United States
- Galderma Research Site — Omaha, Nebraska, United States
- Galderma Research Site — Chapel Hill, North Carolina, United States
- Galderma Research Site — Pflugerville, Texas, United States
- Galderma Research Site — Spring, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.